Post by GE HealthCare

🔬 Advancing the future of precision oncology. We’re launching a novel theranostics study with Mayo Clinic designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer through our Molecular Imaging Biomarker-Based End of Therapy Trial (MI-BET) research collaboration. By combining molecular imaging, clinical outcomes and biomarker insights, researchers aim to better understand how patients respond to therapy and generate evidence that could help inform more individualized treatment decisions in the future. This collaboration builds on our Strategic Radiology Research Alliance with Mayo Clinic and reflects our shared commitment to expanding access and shaping the future of cancer care. 🤝